

CARACO PHARMACEUTICAL LABORATORIES LTD  
Form 8-K  
September 04, 2007

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K**

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

August 13, 2007

(Date of report)

CARACO PHARMACEUTICAL LABORATORIES, LTD.

(Exact name of registrant as specified in its charter)

Michigan  
(State or other jurisdiction of  
incorporation)

0-24676  
(Commission file number)

38-2505723  
(I.R.S. employer identification no.)

1150 Elijah McCoy Drive, Detroit, Michigan 48202

(Address of principal executive offices)

(313) 871-8400

(Registrant's telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 140.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 3.02. Unregistered Sales of Equity Securities**

As of August 28, 2007, registrant issued 1,088,000 shares of common stock to Sun Pharma Global Inc. ( Sun Global ) as a result of the conversion by Sun Global of 1,088,000 shares of Series B Preferred Stock. 544,000 shares of Series B Preferred Stock were originally issued to Sun Global on each of August 22, 2004 and on August 27, 2004 in connection with the transfer of one product on each of such dates pursuant to registrant s products agreement with Sun Global dated November 21, 2002 (the Products Agreement ).

On August 13, 2007, registrant issued Sun Global 544,000 shares of Series B Preferred Stock in exchange for the transfer of one product pursuant to registrant s Products Agreement.

The Series B Preferred Stock may be converted into common stock on a one-for one basis after three years from the date of issuance or following a person (other than Sun Pharmaceutical Industries Limited and its affiliates) acquiring control of registrant.

The Series B Preferred Stock and the underlying common stock were issued pursuant to an exemption from registration under Section 4(2) of the Securities Act of 1933.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**CARACO PHARMACEUTICAL LABORATORIES, LTD.**

Date: September 4, 2007

By:           /s/ Daniel H. Movens            
Daniel H. Movens  
Chief Executive Officer